Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children.


Journal

Journal of pediatric endocrinology & metabolism : JPEM
ISSN: 2191-0251
Titre abrégé: J Pediatr Endocrinol Metab
Pays: Germany
ID NLM: 9508900

Informations de publication

Date de publication:
26 Nov 2020
Historique:
received: 26 03 2020
accepted: 04 08 2020
pubmed: 18 10 2020
medline: 28 8 2021
entrez: 17 10 2020
Statut: ppublish

Résumé

Background Sclerostin and osteoprotegerin (OPG) are new markers of chronic kidney disease (CKD) mediated mineral bone disease (CKD-MBD) which were extensively evaluated in adult population. We aimed to evaluate the associations between serum levels of sclerostin/OPG and parameters of bone turnover and compare the serum levels of sclerostin/OPG in different stages of CKD in children. Methods 70 children with CKD stage 1-5, aged 2-21 years were examined. Serum levels of alkaline phosphatase (ALP), creatinine, total calcium, phosphorus , intact parathyroid hormone (iPTH) and vitamin D were measured. Serum sclerostin and OPG levels were measured in children with different levels of CKD stage and their association with bone turnover parameters were noted. Results We did not observe any significant correlation between serum levels of sclerostin and OPG and stages of CKD. A negative relationship was present between serum sclerostin and 25-OH vitamin D levels. Osteoprotegerin was positively and significantly correlated with ALP but serum sclerostin was negatively correlated with ALP. Conclusion Our study, which includes only children and adolescents with a growing skeleton under uremic conditions and excluding diabetes and atherosclerosis interference, is very valuable. We couldn't find any significant relationship between either sclerostin or OPG levels among different stages of CKD. Also our study demonstared a strong negative relationship between ALP and sclerostin levels and a strong positive relationship between ALP and OPG levels, reminding the importance of ALP levels to predict the bone-mineral status of the children with CKD.

Identifiants

pubmed: 33068383
doi: 10.1515/jpem-2020-0140
pii: /j/jpem.ahead-of-print/jpem-2020-0140/jpem-2020-0140.xml
doi:
pii:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Biomarkers 0
Minerals 0
Osteoprotegerin 0
SOST protein, human 0
TNFRSF11B protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1383-1390

Auteurs

Sercin Guven (S)

Marmara University Medical Faculty, Department of Pediatrics, Division of Pediatric Nephrology, Istanbul, Turkey.

Ibrahim Gokce (I)

Marmara University Medical Faculty, Department of Pediatrics, Division of Pediatric Nephrology, Istanbul, Turkey.

Neslihan Cicek (N)

Marmara University Medical Faculty, Department of Pediatrics, Division of Pediatric Nephrology, Istanbul, Turkey.

Ali Yaman (A)

Marmara University Medical Faculty, Department of Biochemistry, Istanbul, Turkey.

Pinar Vatansever (P)

Marmara University Medical Faculty, Department of Biochemistry, Istanbul, Turkey.

Harika Alpay (H)

Marmara University Medical Faculty, Department of Pediatrics, Division of Pediatric Nephrology, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH